Topic European Commission

News European Commission

• PolyPid Joins Consortium of EU's Seventh Framework Program to Develop Unique Treatment of Biofilm-Associated Infections

  PolyPid, a developer of drug carriers, announced that the European Commission has approved a grant of €1 million to PolyPid, following its joining of a special pan-European consortium, the Biofilm Alliance (BALI), established to develop a unique treatment of biofilm-associated infections. The new tr more

• Commission’s Strategy Launch: EU moves to grow its own Bioeconomy

  The eagerly anticipated EU strategy on the bioeconomy has been adopted by the European Commission.  “This is a milestone moment for Europe and for Europeans” commented Lars Hansen, Chair of EuropaBio’s Industrial Biotech Council. “and, hopefully, it won’t go unnoticed, since it represents a giant le more

• Merck Receives European Approval to Expand Use of Rebif in Patients with Early Multiple Sclerosis

  Merck KGaA announced today that that the European Commission (EC) has approved extension of the indication of Rebif® (interferon beta-1a), Merck’s leading treatment for relapsing forms of multiple sclerosis (MS). This EC approval is for the use of Rebif 44 micrograms three times weekly in patients w more

Publications European Commission

• Determination of glyceroltriheptanoate (GTH) in processed animal by‐products by GC‐FID

  Abstract The European Regulation concerning animal by‐products established rules on safe use, transportation and disposal of these materials. According to the health risks, the products were sorted in three categories, and the materials belonging to category 1 and 2 (high and intermediate health more

• Enabling personalized medicine in Europe: a look at the European Commission’s funding activities in the field of personalized medicine research

  The potential benefits that personalized medicine approaches can bring to healthcare are discussed with much interest throughout the EU. This novel approach is based on a better understanding of the molecular mechanisms of health and disease and it has now begun to show results. There is, however, a more

• Phenylketonuria: nutritional advances and challenges

  Despite the appearance of new treatment, dietary approach remains the mainstay of PKU therapy. The nutritional management has become complex to optimize PKU patients' growth, development and diet compliance. This paper review critically new advances and challenges that have recently focused atten more

Market studies European Commission

• Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success

  GBI Research, the leading business intelligence provider, has released its latest research “Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success” which provides an insight into the different endpoints tha more

• Greece Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: The challenges facing drugmakers in Greece in 2012 will be considerably tougher than those faced in 2011. With the introduction of new cost-containment legislation in March 2012, the Greek government can now exercise much greater control over its pharmaceutical budgets and, through the inc more

• Lithuania Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: Lithuania’s drug market is expected to post a gradual recovery over the next five years, but with a short-term worsening economic environment. Public and private consumption will be under pressure in 2012, supporting our assumption that this year’s year-on-year (y-o-y) growth will not be a more

Websites European Commission